On November 13, 2020, the FDA approved pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA approved test.
Last Modified on September 26, 2023